M&A

How a Dexcom-Insulet combination would shake up the diabetes treatment industry
Medtech Dive
Thu, 05/26/22 - 10:52 am
Medtech
devices
diabetes
DexCom
Insulet
M&A
Baxter raises forecasts for Hillrom synergies, allaying concerns over $10.5B takeover
Medtech Dive
Thu, 05/26/22 - 10:51 am
Medtech
devices
Baxter
Hill-Rom
M&A
How Vaccine Cash Could Fuel Pfizer's Future Growth
Motley Fool
Wed, 05/25/22 - 11:33 pm
Pfizer
vaccines
M&A
COVID-19
Pfizer's Arena goal? Get out of the way and don't 'break the new toy'
Fierce Biotech
Tue, 05/24/22 - 10:38 am
Pfizer
M&A
Arena Pharmaceuticals
25 Most Attractive Medtech M&A Targets in 2022
Medical Devices and Diagnostics Industry
Mon, 05/23/22 - 10:33 am
Medtech
devices
M&A
AtriCure
Axonics
Cardiovascular Systems
Conmed
Glaukos
Inari Medical
InMode
Inspire Medical Systems
iRhythm Technologies
NeuroPace
Nevro
NuVasive
OrthoPediatrics
Paragon 28
Penumbra
Pulmonx
Shockwave Medical
SI-BONE
Silk Road Medical
Staar Surgical
Tandem Diabetes
Treace Medical Concepts
TELA Bio
ViewRay
Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio
BioSpace
Mon, 05/23/22 - 10:17 am
Alcon
M&A
Eysuvis
dry eye
Sanofi's $20B buyout of Genzyme pays off again with European OK for first Niemann-Pick drug
Endpoints
Fri, 05/20/22 - 10:30 am
Sanofi
Genzyme
M&A
Europe
Niemann-Pick disease
Xenpozyme
olipudase alfa
Amgen celebrates 25 years of deCODE Genetics as partnership evolves from discovery to development
Fierce Biotech
Fri, 05/20/22 - 10:16 am
Amgen
M&A
deCODE Genetics
drug discovery
drug development
Big pharma’s biggest spenders revealed
EP Vantage
Tue, 05/17/22 - 10:29 am
R&D
licensing
M&A
COVID-19
Big Pharma
Bristol Myers Squibb
JNJ
AbbVie
Sanofi
Merck
Novartis
Pfizer
AstraZeneca
Roche
GSK
Eli Lilly
Orphazyme agrees to sell itself, and its 'pipeline-in-a-product,' to KemPharm
Endpoints
Mon, 05/16/22 - 10:20 am
Orphazyme
KemPharm
M&A
arimoclomol
Checkmate details bleak future if $250M Regeneron merger does not close
Fierce Biotech
Sun, 05/15/22 - 11:17 pm
Checkmate Pharmaceuticals
Roche
M&A
Was This Acquisition a Smart Move for GlaxoSmithKline?
Motley Fool
Sun, 05/15/22 - 11:10 pm
GSK
Sierra Oncology
momelotinib
bone marrow cancer
M&A
Pfizer Turns to Unusual Deal Structure to Buy Biohaven Drugs
Yahoo/Bloomberg
Fri, 05/13/22 - 10:38 am
Pfizer
Biohaven
M&A
Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
Medtronic Hits an FTC Roadblock in Intersect ENT Deal
Medical Devices and Diagnostics Industry
Wed, 05/11/22 - 11:02 pm
Medtech
devices
Medtronic
FTC
M&A
Intersect ENT
Cortexyme shakes things up with Novosteo acquisition, leadership change and a new name
Fierce Biotech
Tue, 05/10/22 - 10:32 pm
Cortexyme
Novosteo
M&A
Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs
BioPharma Dive
Tue, 05/10/22 - 10:57 am
Pfizer
M&A
Biohaven
migraines
For medtechs seeking deals, it’s hurry up and wait
EP Vantage
Mon, 05/9/22 - 09:56 am
Medtech
devices
IPOs
M&A
Next Biogen CEO's most-prized expertise? Dealmaking experience, investors say
Fierce Pharma
Wed, 05/4/22 - 05:34 pm
Biogen
Pharma CEOs
M&A
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?
Motley Fool
Mon, 05/2/22 - 11:57 am
Novartis
M&A
AveXis
Zolgensma
Endocyte
Pluvicto
The Medicines Company
Levqio

Pages